IRONSHORE PHARMACEUTICALS INC.
STOUGHTON, MA

Michele Novotni, Ph.D. is an internationally recognized expert and thought leader in the field of ADHD. She provides tele-coaching and consulting for clients world-wide. She is the former president and CEO of the national Attention Deficit Disorder Association (ADDA), an inspiring speaker, best-selling author, psychologist, coach and parent of a young adult with ADHD. She is co-author of What Does Everybody Else Know That I Don't? and The Novotni Social Skills Checklist. She has been interviewed on hundreds of television and radio stations, been quoted in leading national publications, and served as a keynote or invited presenter throughout the world. Russell A. Barkley, PhD By clicking SUBMIT, you indicate that you’d like to receive information and offers from Ironshore Pharmaceuticals about ADHD including website updates, educational information, product information, product announcements, coupons, market research, and other related information. Our lead products are targeted at helping ADHD patients and their families by leveraging proprietary technologies to address a significant unmet medical need – inadequate control of symptoms of ADHD during the morning routine. Ironshore has developed a proprietary, oral controlled-release technology for evening dosing of medication with delayed and extended release characteristics that is designed to provide for next-day therapeutic activity beginning in the early morning and lasting throughout the day. At Ironshore Pharmaceuticals & Development, Inc. we use proprietary drug-delivery technology to develop improved versions of existing drug products. Ironshore Pharmaceuticals & Development, Inc. is a biopharmaceutical company whose mission is to develop innovative, patient-centric treatment options, utilizing its proprietary DELEXIS® technology, to improve the lives of patients and caregivers. Based in Grand Cayman, Ironshore is responsible for managing all intellectual property, and directing all research, development and manufacturing activities for its drug candidates. Ironshore is a wholly owned subsidiary of Toronto-based Highland Therapeutics Inc. Our lead products are targeted at helping ADHD patients and their families by leveraging proprietary technologies to address a significant unmet medical need – inadequate control of symptoms of ADHD during the morning routine. Ironshore has developed a proprietary, oral controlled-release technology for evening dosing of medication with delayed and extended release characteristics that is designed to provide for next-day therapeutic activity beginning in the early morning and lasting throughout the day. Our lead products are targeted at helping ADHD patients and their families by leveraging proprietary technologies to address a significant unmet medical need – inadequate control of symptoms of ADHD during the morning routine. Ironshore has developed a proprietary, oral controlled-release technology for evening dosing of medication with delayed and extended release characteristics that is designed to provide for next-day therapeutic activity beginning in the early morning and lasting throughout the day. Request for Grant Submissions Info

KEY FACTS ABOUT IRONSHORE PHARMACEUTICALS INC.

Company name
IRONSHORE PHARMACEUTICALS INC.
Status
Active
Filed Number
F17000002610
FEI Number
32-0464445
Date of Incorporation
June 6, 2017
Age - 8 years
Home State
DE
Company Type
Foreign for Profit

CONTACTS

Website
http://ironshorepharmaceuticals.com
Phones
(177) 556-1000
(000) 000-0042
(000) 000-0017
(000) 000-0168
(000) 000-0238
(000) 000-0623
(000) 000-5316
(000) 000-5485
(000) 000-5725
(000) 000-5778
(000) 000-5831
(000) 000-5994
(000) 000-6168
(000) 000-6405
(000) 000-6574
(000) 000-6806
(000) 000-6970
(000) 000-7197
(000) 000-7323
(000) 000-7353
(000) 000-7507
(000) 000-7581
(000) 000-7826
(000) 000-8034
(000) 000-8150
(000) 000-8265
(000) 000-8381
(000) 000-8498
(000) 000-8615
(000) 000-8731
(000) 000-8846
(000) 000-8962
(000) 000-9121
(000) 002-3544
(000) 004-8166
(000) 004-8496
(000) 005-3166
(000) 005-3333
(000) 005-3504
(000) 005-3740
(000) 005-3893
(000) 005-4216
(000) 005-6717
(000) 000-0043
(000) 000-0044
(000) 000-0045
(000) 000-0046
(000) 000-0047
(000) 000-0048
(000) 000-0049
(000) 000-0050
(000) 000-0051
(000) 000-0052
(000) 000-0053
(000) 000-0054
(000) 000-0055
(000) 000-0056
(000) 000-0057
(000) 000-0058
(000) 000-0059
(000) 000-0060
(000) 000-0061
(000) 000-0062
(000) 000-0063
(000) 000-0064
(000) 000-0065
(000) 000-0066
(000) 000-0067
(000) 000-0068
(000) 000-0069
(000) 000-0070
(000) 000-0071
(000) 000-0072
(000) 000-0073
(000) 000-0074
(000) 000-0075
(000) 000-0076
(000) 000-0077
(000) 000-0078
(000) 000-0079
(000) 000-0080
(000) 000-0081
(000) 000-0082
(000) 000-0083
(000) 000-0084
(000) 000-0085
(000) 000-0086
(000) 000-0087
(000) 000-0088
(000) 000-0089
(000) 000-0090
(000) 000-0091
(000) 000-0092
(000) 000-0093
(000) 000-0094
(000) 000-0095
(000) 000-0096
(000) 000-0097
(000) 000-0098
(000) 000-0099
(000) 000-0000
(000) 005-8027
(000) 005-8232
(000) 005-8460
(000) 020-2860
(000) 020-3084
(000) 020-3380
(000) 020-3821
(000) 030-8369
(000) 030-8794
(000) 030-9242
(000) 030-9508
(000) 031-2581
(000) 031-2627

IRONSHORE PHARMACEUTICALS INC. NEAR ME

Principal Address
100 Technology Center Drive,
Suite 300,
Stoughton,
MA,
02072,
US

See Also

Officers and Directors

The IRONSHORE PHARMACEUTICALS INC. managed by the three persons from Stoughton on following positions: Secr, Gene, Chie

Colleen Tupper

Position
Secr Active
From
Stoughton, MA, MA

Shirley Kuhlmann

Position
Gene Active
From
Stoughton, MA, MA

Shirley Kuhlmann

Position
Chie Active
From
Stoughton, MA, MA





Registered Agent is C T CORPORATION SYSTEM

Address
1200 SOUTH PINE ISLAND ROAD, PLANTATION, FL, 33324

Events

October 10, 2018
REINSTATEMENT
September 28, 2018
REVOKED FOR ANNUAL REPORT

Annual Reports

2025
March 13, 2025
2024
April 9, 2024